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Abstract Vasovagal tonus index (VVTI) is an indirect mea-
sure of heart rate variability and may serve as a marker of
disease severity. Higher heart rate variability has predicted
lower tumour burden and improved survival in humans with
various tumour types. The purpose of this pilot study was to
evaluate VVTI as a biomarker of remission status in canine
lymphoma. The primary hypothesis was that VVTI would be
increased in dogs in remission compared to dogs out of remis-
sion. Twenty-seven dogs were prospectively enrolled if they
had a diagnosis of intermediate to high-grade lymphoma and
underwent multidrug chemotherapy. Serial electrocardiogram
data were collected under standard conditions and relation-
ships between VVTI, remission status and other clinical var-
iables were evaluated. VVTI from dogs in remission (partial
or complete) did not differ from dogs with fulminant lympho-
ma (naive or at time of relapse). Dogs in partial remission had
higher VVTI than dogs in complete remission (p = 0.021).
Higher baseline VVTI was associated with higher subsequent
scores (p < 0.001). VVTI also correlated with anxiety level
(p = 0.03). Based on this pilot study, VVTI did not hold any
obvious promise as a useful clinical biomarker of remission
status. Further investigation may better elucidate the clinical
and prognostic utility of VVTI in dogs with lymphoma.
Keywords Lymphoma . Heart rate . Chemotherapy .
Remission . Electrocardiogram
Introduction
Heart rate variability (HRV) is the physiologic variation in the
beat-to-beat interval, or the R-R interval on an electrocardio-
gram (ECG) recording, which correlates with cardiac auto-
nomic tone (Kuo et al. 2005). Variations in R-R intervals
reflect vagal outflow as parasympathetic nerve traffic exerts
its effects much faster than sympathetic outflow (Task Force
1996). In people, HRV is an index of cardiovascular and mor-
tality risk in health and cardiac and renal disease (Tsuji et al.
1996; Kiviniemi et al. 2007; Oikawa et al. 2009). Several
studies have investigated HRV in healthy and unhealthy dogs,
with diseases including myocarditis, myxomatous mitral
valve disease and diabetes mellitus, suggesting a role for
VVTI as a predictive or prognostic biomarker (Calvert and
Wall 2002; Doxey and Boswood 2004; Pereira et al. 2008;
Manzo et al. 2009; Oliveira et al. 2012; Pirintr et al. 2012;
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Rasmussen et al. 2012; López-Alvarez et al. 2014; Martlé
et al. 2014; Bogucki and Noszczyk-Nowak 2015).
The vagus nerve may be intricately involved in human
cancer as part of an inflammatory reflex, in which tumour-
mediated inflammation triggers vagal afferent traffic to the
brain to modulate immune and neuroendocrine function
(Tracey 2002; Gidron et al. 2005; Mravec et al. 2006;
Gidron and Ronson 2008; Golan et al. 2009; Rosas-Ballina
and Tracey 2009; Irwin and Cole 2011; Olofsson et al. 2012).
Recent studies have investigated the prognostic value of HRV
in human cancer patients. Higher HRV was associated with
longer survival time, and predicted lower tumour burden and
improved survival in patients with various solid tumours
(Dekker et al. 1997, Hoffmann et al. 2001, Chiang et al.
2010, Fadul et al. 2009, Giese-Davis et al. 2015, Guo et al.
2015, Kim et al. 2015). Thus HRV has potential in oncology
as a biomarker of response to chemotherapy and overall prog-
nosis (De Couck and Gidron 2013; Giese-Davis et al. 2015).
Vasovagal tonus index (VVTI) is a time domain indicator of
HRV that quantifies high-frequency variations in heart rate.
VVTI measurement is rapid, non-invasive and uncomplicated
because it can be calculated from ECG recordings using a
simple mathematical formula. Its prognostic value has been
demonstrated in dogs with congestive heart failure secondary
to both dilated cardiomyopathy and myxomatous mitral valve
disease (Häggström et al. 1996; Doxey and Boswood 2004;
Pereira et al. 2008; López-Alvarez et al. 2014). If VVTI is a
reliable biomarker of disease severity, it may therefore have
widespread clinical potential. Recognizing that humans with
higher disease burden have significantly lower HRV compared
to patients with earlier cancer stages (Entschladen et al. 2004;
Gidron et al. 2005; Mantovani et al. 2008; De Couck et al.
2012; De Couck and Gidron 2013), we elected to evaluate
the ability of VVTI to detect tumour burden in dogs with lym-
phoma. Lymphoma burden decreases rapidly in most dogs fol-
lowing chemotherapy, thereby permitting VVTI comparisons
within each dog and across groups of dogs. The primary hy-
pothesis of this study was that vagal tone, and therefore HRV,
would increase in dogs with intermediate to high-grade lym-
phoma when in remission with multidrug chemotherapy.
Material and methods
Dogs
Client-owned dogs with multicentric non-Hodgkin’s lympho-
mawere prospectively enrolled at a specialty oncology service
between January 2014 and September 2015. Inclusion criteria
were: stage III-V intermediate and high grade lymphoma di-
agnosed by cytology or histology, treatment with standardised
multidrug (cyclophosphamide, hydroxydaunorubicin, vincris-
tine, prednisone or CHOP) chemotherapy and client consent
(Macdonald et al. 2005). As this was a pilot study, dogs were
enrolled at any stage of treatment or remission, including at
diagnosis, while undergoing chemotherapy or during routine
monthly monitoring for relapse.
Exclusion criteria included evidence of behavioural aggres-
sion, systemic diseases or obvious pre-existing cardiac disease
identified from a combination of clinical history, physical ex-
amination and/or echocardiography. Pre-chemotherapy echo-
cardiography was at the discretion of the clinician, and prin-
cipally performed to identify subclinical cardiac disease prior
to administration of doxorubicin. The study was approved by
the Institutional Veterinary Ethics and Review Committee.
ECG recordings and VVTI measurements
Standard 6-lead ECGs were recorded and printed (50 mm/s)
with a multi-channel ECG machine (Schiller AT-102 Plus™)
collected at every chemotherapy or follow-up visit. All record-
ings were obtained from unsedated dogs placed in right lateral
recumbency in a dimly-lit room at least 2 h following admis-
sion. ECG leads were attached with atraumatic clips and alco-
hol (95% ethanol, 5% methanol; Surgical Spirit™, Vet Way
Ltd., Elvington York, UK) and no electronic filters were ap-
plied. ECG trace analysis was performed manually on the first
available 20 consecutive R-R intervals of sinus origin. Each
dog was scored during ECG acquisition according to a 5-point
rising scale of anxiety (Table 1). This anxiety score was gen-
erated by the authors using elements from anxiety scores pre-
viously published (Beata et al. 2007; Frank et al. 2006). R-R
intervals were measured in millimetres and converted into
milliseconds. VVTI was calculated as the natural logarithm
of the variance of 20 consecutive R-R intervals as previously
described (Häggström et al. 1996). This was performed by one
member of the Cardiology Service (BS) who was blinded to
the clinical information. Follow-up ECGs were scheduled at
monthly intervals for the first 18 months, followed by every
other month for 18 months.
Clinical data
Signalment was collected for each dog as well as clinical data
where available, including the presence or absence of
hypercalcaemia, stage, substage, immunophenotype,
Table 1 Anxiety
scoring Anxiety score 0 = no; 1 = yes
Attempt to rise
Stiff / tense
Panting
Limb withdrawal
Awake
Overall score /5 =
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chemotherapy drugs and dosages administered, remission sta-
tus, duration to remission, duration to first relapse, and devel-
opment of chemotherapy-induced toxicity. Full staging was
recommended for all dogs at diagnosis, however not always
pursued according to clients’ wishes. Minimal staging, which
included lymph node measurements, haematology and bio-
chemistry, was performed in all dogs prior to initiation of
chemotherapy. Remission status was determined using
standardised criteria (Vail et al. 2010). Dogs with overt lym-
phoma at the time of initial diagnosis or at time of relapse were
documented as Bout of remission (OR)^ while remission sta-
tus was divided as partial remission (PR) or complete clinical
remission (CR). At each chemotherapy visit, lymph node
measurements, physical exam and haematology was per-
formed. Chemotherapy-induced toxicity was recorded using
standardised Veterinary Cooperative Oncology Group
(VCOG) criteria (VCOG 2011). At time of relapse, repeat
CHOP was offered. For dogs that failed CHOP chemotherapy
(relapsed disease during CHOP), lomustine and prednisolone
was offered as first-line rescue therapy.
Statistical analysis
Statistical analyses were performed (IH) using the R
Statistical System (R Core Team. R: A language and envi-
ronment for statistical computing. R Foundation for
Statistical Computing (R Core Team 2015) . Available at:
https://www.R-project.org/.). VVTI scores were compared
using linear models (estimated with lme function of the R
nlme package) (Pinheiro et al. 2017). Case identifier was
included as a random effect on the model intercept to re-
duce the impact of pseudo-replication when measurements
were repeated within dogs. A first order autocorrelation
term was included as VVTI measurements demonstrated
autocorrelation on exploratory analysis (using the AR1
function of the R nlme package). The significance of mod-
el terms was assessed using likelihood ratio tests (LRT) on
the addition of the terms. Models assessing impact of re-
mission status used categorical remission status as a single
fixed effect. Remission status was retained as a fixed effect
in models assessing anxiety, substage and age. The associ-
ation between baseline VVTI and later VVTI was de-
scribed by Pearson product moment correlation coefficient
and estimated with a random effects linear model.
Predictability of remission by means of a VVTI was eval-
uated with a binary logistic regression model. The study
involved multiple statistical tests in the exploration of hy-
potheses. No explicit corrections were made for this; p-
values are presented as-is. Data are expressed as mean,
median and range. A p-value of <0.05 was considered sta-
tistically significant for reporting of final variables from
the models.
Results
Twenty-seven dogs with a diagnosis consistent with non-
Hodgkin’s lymphoma were enrolled in the study.
Demographics and clinical data for all dogs are shown in
Table 2. Twelve dogs had echocardiography prior to doxorubi-
cin administration. A total of 249 VVTIs were obtained, with a
mean andmedian of 9 scores/dog and 7 scores/dog (range of 1–
31 scores/ dog). Sixteen dogs (59%) had a baseline VVTI at
initial diagnosis (chemotherapy-naïve disease) while the re-
maining dogs were enrolled following initiation of chemother-
apy. Of the 16 dogs with baseline VVTI scores,14 had serial
VVTI scores while in PR or CR; 2 dogs did not achieve remis-
sion (Fig. 1). Of the 11 dogs lacking baseline VVTI data prior
to initiation of chemotherapy, four dogs relapsed over time,
providing a VVTI when OR at least once.
No significant differences were detected between VVTIs
from dogs that were OR (median 7.48, range 3.98–11.39,
n = 38) compared to dogs in either PR or CR (Fig. 2).
Compared to CR tracings (median 7.54, range 3.90–12.33,
n = 143), VVTI was higher in PR tracings (median 8.12, range
4.8–11.26, n = 61) with a mean difference of 0.59 (p = 0.021)
(results with interquartile ranges in Table 1). Seven scores were
obtained from dogs with stable disease (SD) or progressive
disease (PD) and these scores were not included in analysis.
Dogs with higher baseline scores were more likely to have
higher subsequent scores when in partial or complete remis-
sion (Fig. 1); for every unit increase in baseline VVTI, there
was an average 0.62 increase in VVTI (p < 0.001). VVTI was
associated with anxiety level, with decreasing VVTI as anxi-
ety increased (p = 0.03). VVTI did not differ between dogs
with substage a and b lymphoma (p = 0.28). Likewise, VVTI
did not correlate with sex, age, lymphoma stage, hypercalce-
mia, chemotherapy-induced adverse effects, chemotherapy
status (receiving or not receiving concurrent chemotherapy,
number of treatments, number of doxorubicin treatments),
breed or brachycephalic phenotype.
Discussion
This is the first study to investigate the use of VVTI in canine
cancer. Humans withmore advanced cancer, have been shown
to have significantly lower HRV compared to patients with
earlier cancer stages (Entschladen et al. 2004; Gidron et al.
2005; Mantovani et al. 2008; De Couck et al. 2012; De Couck
and Gidron 2013). As disease burden in canine lymphoma
decreases rapidly following the initiation of chemotherapy,
canine lymphoma was a reasonable initial model disease in
which to evaluate VVTI, thereby permitting comparisons
within each dog and across groups of dogs.
While VVTI was significantly higher for dogs in PR
compared to in CR, VVTI in either of these stages did
Vet Res Commun
not differ from OR. Therefore the null hypothesis was cor-
rect. The results were unexpected, as theoretically, de-
creased lymphoma burden in dogs in CR compared to tu-
mour burden in PR would lead to decreased sympathetic
tone, increased parasympathetic tone and thus increased
VVTI. Similarly, it was expected that dogs in either CR
or PR would have increased VVTI compared to dogs that
were OR. Although it is unclear how HRV directly corre-
lates to human cancer, a bi-directional relationship has
been hypothesised. Higher disease burden was thought to
decrease heart rate variability due to inflammation, oxida-
tive stress and sympathetic activation. Vagal tone however
is not only a consequence of tumour burden but it is also
suspected to actively modulate tumour growth through
anti-inflammatory effects via two separate ways. Via affer-
ent vagal nerve fibres, the hypothalamic-pituitary-adrenal
axis can be activated, leading to the production of cortico-
steroids and an anti-inflammatory response. Via efferent
fibres, anti-inflammatory signals can be transmitted via
acetylcholine to activate receptors on tissue macrophages
and suppress cytokine synthesis (Gidron et al. 2005;
Mravec et al. 2006). Prior studies have shown that there
is a worse prognosis in cancer when there is not an intact
vagus; moreover, a causal relationship was shown between
vagal nerve activation and reduced tumour volume (Erin
et al. 2004; Erin et al. 2008; Erin et al. 2012). This bi-
directional relationship between cancer burden and heart
rate variability hampers a simplistic interpretation of
higher tumour burden that results in a lower HRV and thus
may offer an explanation for the unexpected results.
Dogs with higher baseline values were found to have
higher subsequent VVTI scores when in remission. This sug-
gests that there may be baseline variation across dogs regard-
less of intra-dog score variability. Previously a range of scores
with marked variability across breeds of dogs has been pub-
lished (Doxey and Boswood 2004). However, in this study, it
is not the absolute value of VVTI that is important but rather
the change from baseline. Brachycephalic dogs have higher
vagal tone and higher VVTI, and while brachcephaly may
have affected the degree to which VVTI changed from base-
line, only three dogs were brachycephalic, making it unlikely
that this significantly impacted the chance to detect a
Table 2 Summary of clinical
data from 27 dogs with
lymphoma in which vasovagal
tonus index (VVTI) was
measured
Clinical Characteristics (N = 27 dogs)
Age (years) Median (Range) 8 (2.25–11.91)
Sex M 18 (67%)
F 9 (33%)
Body weight (kg) Median (Range) 26.6 (6.3–75.5)
Breed Labrador 4 (15%)
Border Collie 3 (11%)
Boxer 3 (11%)
Rottweiler 2 (7.5%)
WHWT 2 (7.5%)
Cross 3 (11%)
Other (<2) 10 (37%)
Breed type Brachycephalic 3 (11%)
Stage Stage III 9 (33%)
Stage IV 15 (56%)
Stage V 3 (11%)
Substage Substage a 19 (70%)
Substage b 8 (30%)
Hypercalcemia 5 (19%)
Immunophenotype B-cell 4 (80% of samples tested)
T-cell 1 (20%)
VVTI total scores 242 38 OR
61 PR
143 CR
VVTI measures OR (mean 7.77 median 7.48 IQ 6.58–9.08)
PR (mean 8.00 median 8.12 IQ 6.81–8.93)
CR (mean 7.54 median 7.54 IQ 6.55–8.33)
WHWT West Highland White Terrier, OR out of remission, PR partial remission, CR complete remission, IQ
Interquartile range
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correlation between VVTI scores and remission status.
Statistical analysis did not show any significant correlation
between VVTI score and brachycephalic phenotype.
Higher anxiety scores were associated with lower
VVTI. The protocol to obtain ECG was designed to min-
imise anxiety during collection of data, however some
Fig. 2 Box andWhisker plot demonstrating the distribution of vasovagal
tonus index (VVTI) values across remission status for the 27 dogs en-
rolled; horizontal line represents the median, the X represents the mean of
scores. VVTI was significantly higher in dogs in partial remission (PR)
compared to dogs in complete remission (CR). VVTI from dogs with
fulminant lymphoma either at initial diagnosis or at time of relapse (out
of remission = OR) were not significantly different from dogs in partial
and/or complete remission
Fig. 1 Vasovagal tonus index
(VVTI) values per dog in differ-
ent remission statuses for dogs
with available baseline scores at
time of initial diagnosis (out of
remission = OR) and subsequent
partial remission (PR) and/or
complete remission (CR) values
(N = 14). Baseline VVTI is rep-
resented by a +
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dogs still demonstrated signs of anxiety and further mod-
ifications such as prolonged acclimatisation or permitting
owner presence in future studies may further reduce anx-
iety. As the change in VVTI from baseline was important
in this study and anxiety scores did not increase in each
dog over time the fact that VVTI scores from dogs in PR
was higher than dogs in CR suggests the level of anxiety
did not significantly influence our findings.
Dogs in which concurrent cardiac disease was
suspected were not included. Echocardiography was not
performed in all dogs prior to the first dose of doxorubi-
cin. It is possible that dogs with subclinical cardiac dis-
ease were included in this study. While inclusion criteria
could have required an echocardiogram prior to treat-
ment, published literature in dogs with mitral valve dis-
ease suggests that subclinical cardiac disease would not
have significantly affected VVTI (Häggström et al.
1996). Moreover, echocardiogram cannot predict
doxorubicin-induced cardiotoxicity in dogs, calling into
question its necessity prior to treatment (Ratterree et al.
2012; Tater et al. 2012).
Fewer values were obtained of dogs with fulminant
lymphoma compared to dogs in PR or CR for multiple
reasons. As canine non-Hodgkin’s lymphoma is rapidly
proliferative, rapid remission is achieved in most dogs
within one to three weeks of starting chemotherapy.
Therefore, dogs contributed more scores when in PR or
CR compared to when OR. This study was designed to
include dogs already receiving chemotherapy and there-
fore without baseline values. This was deliberate in order
to maximize the number of dogs recruited to the study and
to increase the number of samples for analysis. It also
ensured that the chemotherapy was initiated at time of
diagnosis without delay in treatment to obtain baseline
VVTI scores, as sedation was often used for diagnostics.
The impact of chemotherapy on VVTI is unclear al-
though in human oncology, reduced HRV was found fol-
lowing treatment with anthracyclines (Tjeerdsma et al.
1999). Doxorubicin treatments as part of the CHOP pro-
tocol in our study may have influenced the VVTI scores
in this population, however exploratory analysis did not
show any obvious correlation of VVTI with increasing
numbers of doxorubicin doses or chemotherapy treat-
ments overall. Additionally, VVTI values from dogs on
chemotherapy were not markedly different from dogs off
chemotherapy following completion of their protocol. It
was not the primary aim of this pilot study to accurately
evaluate associations between VVTI and clinical vari-
ables other than remission status, however it was inter-
esting to evaluate for hypothesis-generation purposes.
Likewise, as the study involved multiple statistical com-
parisons there was a risk of increased type I errors. There
were no clear associations with multiple clinical
variables and VVTI, and although it is possible that a
larger study could reveal an association, VVTI may in-
stead be an independent variable.
Conclusions
In conclusion, there were no significant differences in VVTI
between dogs in remission compared to dogs with overt lym-
phoma in this initial pilot study. Surprisingly, PRVVTIs were
higher than VVTIs of dogs in CR. This is the first study to
indicate that VVTI varies over the course of canine lymphoma
treatment. Further studies will be essential to improve under-
standing of the pathophysiology of autonomic tone in dogs
with lymphoma or other neoplastic diseases. A larger study
population will be required to determine if clear prognostic
potential exists, as has been shown in humans.
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